Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in BFLY.

← Back to Free Index

BFLY

Analysis as of: 2026-06-21

Butterfly Network, Inc.

Butterfly Network sells handheld ultrasound devices, cloud workflow software, and embedded ultrasound-chip technology to clinicians, health systems, and development partners.

ai hardware healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Good Platform, Harder Stock From Here

A credible path exists from niche handheld imaging vendor to regulated workflow and chip platform. But after the June 2026 rerating, the next leg higher needs proof that software, home-care, and Embedded economics are durable rather than merely promising.

Analysis

Thesis

Butterfly can still compound into a broader regulated imaging platform as AI lowers training friction and expands ultrasound into more settings, but after the June 2026 rerating the stock now needs real proof that software, home-care workflows, and Embedded licensing become durable value-capture layers rather than interesting add-ons.

Last Economy Alignment

AI should make ultrasound easier to acquire, document, and deploy, which expands demand while Butterfly still controls regulated hardware and workflow touchpoints. It is a real beneficiary, but not a foundational winner, because larger imaging vendors and approval gates can still cap value capture.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.2x (from 5 most recent analyses)

Reasoning

Butterfly can plausibly grow revenue several-fold as handheld ultrasound adoption expands and higher-margin software and Embedded revenue deepen the model. The stock already discounts much of that optionality after the June spike, so upside from here depends less on raw probe growth and more on proving a sticky workflow, licensing, and community-care layer.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is not whether Butterfly’s core device works; it does. The real risk is whether management can turn a good handheld ultrasound product into a stickier operating layer before approvals, supplier concentration, and larger imaging vendors blunt the transition. After the mid-June stock spike, valuation risk is now as important as execution risk.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

By June 18, 2026, shares had surged to roughly 8.9, lifting market cap to about 2300 and sharply raising valuation risk versus early June.
I found no investor-relations announcement yet for the first Home & Community Care commercial agreement or the Beam Steering API launch, so both remain open proof points.
No Q2 2026 earnings date was posted on investor relations as of June 21, 2026; the next major scorecard is still ahead.

Thesis update

The core platform thesis is intact, but the center of gravity shifted from proving basic demand to proving that mix quality and recurring capture can justify a much higher starting valuation.

Forecast update

The stock rerated faster than fundamentals de-risked, so even a constructive 2031 operating outcome now translates into more muted upside unless software, network, and licensing layers scale faster than expected.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.51

They control a real device-and-workflow choke point, so AI can make ultrasound easier to use and expand demand rather than replace them. The risk is that bigger imaging vendors and regulatory gates keep them as a good probe maker instead of the operating layer.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$5.56

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research